Statement
5 Nov 2025
WIPO Standing Committee on Patents (SCP 37): Technology Transfer
On 5 November 2025, IFPMA delivered a statement on technology transfer at the WIPO Standing Committee on Patents (SCP 37) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which is...
Read more
Statement
4 Nov 2025
WIPO Standing Committee on Patents (SCP 37): Patents and health
On 4 November 2025, IFPMA delivered a statement on patents and health at the WIPO Standing Committee on Patents (SCP 37) in Geneva. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global research-based biopharmaceutical industry. We appreciate the opportunity to address the Committee on patents and health. Intellectual property is fundamental to...
Read more
Position paper
27 Oct 2025
Policy considerations for the development, regulation and adoption of biosimilars
Biosimilars can play a role in expanding patient access to biological medicines and in supporting the sustainability of healthcare systems. To fully realize this potential, IFPMA recommends the adoption of a series of policy recommendations.
Read more
